Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

acute,

mild-to-moderate ulcerative colitis

Poster Presentation: Tuesday, October 16, 2007, Exhibit Hall B, #953

-- Long-term remission rates in patients with mild-to-moderate ulcerative

colitis who require a LIALDA dose increase to induce initial remission

Poster Presentation: Monday, October 15, 2007, Exhibit Hall B, #614

About LIALDA

LIALDA is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of LIALDA have been established for up to eight weeks. LIALDA is the first new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients.

Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the U.S., Canada, Europe -- known as MEZAVANT(TM) -- (excluding Italy) and the Pacific Rim. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX Technology.

For more information about LIALDA and for Full Prescribing Information, please visit http://www.LIALDA.com.

Important Safety Information

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond eight weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to sali
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 TB ... and developing better, faster and affordable treatments, announced ... Senior Vice President, External Affairs. Mr. Brock comes ... Head of Major Donor Relations for WWF International ... his role, Mr. Brock will guide the TB ...
(Date:7/31/2014)... und KISSING, Deutschland, 31. Juli ... und Distributor eines computerunterstützten („robotischen") Koloskopie-Systems für ... (Homi) Shamir , ein weltweit anerkannter Manager ... und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener globaler Visionär ...
(Date:7/31/2014)... , July 31, 2014 Nutrastar International ... producer and supplier of premium branded consumer products, including ... and specialty foods, today announced the signing of its ... and its expansion to Hubei Province ... Central China . ...
Breaking Medicine Technology:TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... Feb. 9, 2011 Reportlinker.com announces that a ... catalogue: European Market for Dental ... http://www.reportlinker.com/p0377961/European-Market-for-Dental-Prosthetics-and-CAD/CAM-Devices-2011.html In 2010, ... crowns, bridges and dentures, were valued at over ...
... 2011 Protect Pharmaceutical Corporation (OTC Bulletin Board: ... of two patents and patents-applications to Grunenthal GmbH, a German ... discovery and research. The patent portfolio includes innovative pain drugs ... Ram Sesha, Protect,s Chief Operating Officer, said, "We are ...
Cached Medicine Technology:Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011 2Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... By Randy Dotinga ... -- The parasite that causes malaria is growing increasingly resistant ... new surveillance reports. But several new drugs are in development, ... new hope against this global killer. "Although there has ... the battle against malaria is far from won, and there ...
(Date:7/31/2014)... -- Recovery time after surgery may be reduced for ... to a new study. The study,s Irish researchers ... response, reducing the amount of time surgical patients, wounds ... true among people who tend to have healing complications. ... prescribed medications in the world. While they are typically ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... launched a new online reputation management service named ... as well as organizations get rid of Pissed ... the result of extensive research. ReputationChief.Com management assigned ... service for those who are struggling in their ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Certified Internet Marketing Company, has introduced a new ... quite affordable.     , Ethane Web Technologies has designed ... the expectations of clients and Java Development service ... has given the company a confidence to promise ...
Breaking Medicine News(10 mins):Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2
... Biosciences LLC, a Boston-based company conceived in partnership ... today that Johnson & Johnson has joined the ... will have the opportunity to invest in the ... to fundamentally transform drug discovery and development and ...
... Limited (Nasdaq: WCRX ) announced today that ... close on Tuesday, January 27, 2009. In addition to ... Executive Officer and Paul Herendeen, Executive Vice President and ... audio webcast to discuss the 2009 Financial Guidance for ...
... Keystone Symposium - Obesity: Novel Aspects of the Regulation ... Genetics, Inc. (NYSE Alternext US: ILI) announced today that ... role genetics play in an individual,s ability to lose ... during tomorrow,s Keystone Symposium titled, "Obesity: Novel Aspects of ...
... Blood Bank is honored to announce that it has ... of Cellular Therapy ("FACT"). CORD:USE is a leading ... processing, storage and distribution of donated cord blood. ... more than 14,000 patients with over 70 life-threatening diseases ...
... DIEGO, Jan. 22 Aero Financial, Inc, a strategic ... that the company has been retained as a strategic ... distributor of natural health information and nutrition products.Pursuant to ... Finest(TM) in several facets of the company,s growth plans, ...
... for 11:00 a.m. ET POWAY, Calif., Jan. 22 ... provider of diagnostic imaging products and services that improve ... before the market opens on Thursday, February 5, 2009, ... December 31, 2008. A conference call is scheduled for ...
Cached Medicine News:Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 2Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 3Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 3Health News:CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy 2Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: